March 12, 2018 07:31 AM EDT

Regeneron boosted, rival Esperion slammed as investors scramble to catch up to a PCSK9 price war

John Carroll

Editor & Founder

The big news over the weekend headlined at #ACC18 in Orlando, as Regeneron $REGN and Sanofi $SNY pulled the covers off of data showing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

view job offer post your job now

TRENDING NOW

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B